Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 2038-2044

  Iwamoto, Masayoshi ^a   Kawada, Kenji ^a   Nakamoto, Yuji ^a   Itatani, Yoshiro ^a   Inamoto, Susumu ^a   Toda, Kosuke ^a   Kimura, Hiroyuki ^b   Sasazuki, Takehiko ^c   Shirasawa, Senji ^d   Okuyama, Hiroaki ^e   Inoue, Masahiro ^e   Hasegawa, Suguru ^a   Togashi, Kaori ^a   Sakai, Yoshiharu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

18F FDG PET scans; Colon cancer; Glucose metabolism; Imaging; KRAS

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; GLUCOSE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RADIOPHARMACEUTICAL AGENT; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE PAIRING; CODON; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CTNNB1 GENE; GENE FREQUENCY; GENE MUTATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RETROSPECTIVE STUDY; RNA INTERFERENCE; TGFBETA RII GENE; TUMOR VOLUME; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL HYPOXIA; COLORECTAL TUMOR; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS; RADIOPHARMACEUTICALS; RAS PROTEINS;

EID: 84915752926     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.142927     Document Type: Article

References (22)

1. Karapetis CS, Shirin K-F, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
3. Denko NC. Hypoxia, HIF1 and glucose metabolism in solid tumour. Nat Rev Cancer. 2008;8:705-713.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
5. Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010;176:2292-2301.
6. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50(suppl 1):43S-54S.
7. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
9. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820-1827.
10. 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res. 2012;18:1696-1703.
11. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993;260:85-88.
12. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336-1338.
13. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-1790.
14. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555-1559.
15. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res. 2009;69:8499-8506.
16. 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009;50:1364-1370.
17. Patra KC, Wand Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213-228.
18. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
19. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325:784-791.
20. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and down-stream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009;100:1087-1094.
21. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum. 2011;54:1170-1178.
22. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656-670.